Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|September 7, 2023
Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation frameworkEmma Eckernäs, Jeroen Koomen, Christopher Timmermann, et al.European Journal of Clinical Pharmacology|December 7, 2007
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in ZimbabweChristopher Nyakutira, Daniel Röshammar, Emmanuel Chigutsa, et al.International Journal of Clinical Pharmacology and Therapeutics|September 5, 2012
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clampHans Ericsson, Daniel Röshammar, Maria Wollbratt, et al.The AAPS Journal|September 14, 2011
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyDinko Rekić, Oskar Clewe, Daniel Röshammar, et al.Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.CPT: Pharmacometrics & Systems Pharmacology|August 4, 2025
Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual PatientsFianne Sips, Marco Virgolin, Giuseppe Pasculli, et al.Clinical Pharmacokinetics|July 12, 2011
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjectsJackson K Mukonzo, Sarah Nanzigu, Dinko Rekić, et al.British Journal of Clinical Pharmacology|November 11, 2018
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patientsMagnus Åstrand, Carl Amilon, Daniel Röshammar, et al.British Journal of Clinical Pharmacology|November 18, 2009
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in UgandansJackson K Mukonzo, Daniel Röshammar, Paul Waako, et al.International Journal of Molecular Sciences|February 13, 2026
NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple SclerosisGiulia Russo, Fianne Sips, Simona Catozzi, et al.Pageof 3